A drug delivery company - Dermatrends, Inc. – has entered into an agreement with Teikoku Pharma USA (8887877) to develop a prototype patch formulation for the transdermal delivery of a widely used anti-psychotic pharmaceutical compound.
The terms of agreement include the following:
- Dermatrends will be providing the drug delivery technology for transdermal delivery of an anti-psychotic drug that was selected by Teikoku.
- Dermatrends will utilize its standardized developmental process for effective transdermal delivery.
A world leader in innovative, high-quality drug delivery systems - Teikoku Pharma USA, Inc. – (in addition to its proprietary products) is responsible for the technology and platform of well known branded products including Flector® (Diclofenac Epolamine) and the widely used Lidoderm® (a lidocaine patch marketed by Endo Pharmaceuticals Inc.).
According to Dermatrends CEO Ted Schwarzrock:
Find more details from the press release (a pdf file)."We have produced positive efficacy results for many of our products, including similar compounds to the one we are testing for Teikoku. Our mission is to help demonstrate Dermatrends' patented hydroxide releasing agent (HRA) technology can be combined with the chosen active pharmaceutical ingredient (API) to produce a proprietary pharmaceutical product for our new partner.
There are millions of people who rely on anti- psychotic medication but who cannot be relied upon to take their oral dosage without supervision. Transdermal delivery of this drug represents a large untapped market. We believe that transdermal delivery could be a preferred method of delivery for many patients and their caregivers, representing an important new market opportunity."
Comment Preview